dipyridamole has been researched along with Brain Ischemia in 128 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 9.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| "Treatment with combined Asp/ER-DP vs clopidogrel in 1360 patients with acute, mild ischemic stroke did not differ in terms of effects on functional outcome, recurrence, death, bleeding, or serious adverse events." | 9.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "This pilot study showed equal efficacy and tolerability of the combination group and aspirin alone in acute intervention treatment for prevention of recurrent stroke or vascular death within 6 months." | 9.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 9.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 9.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| "It is unlikely that dipyridamole leads to a permanent reduction in blood pressure and that this would explain why this drug might prevent strokes rather than coronary events." | 9.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "Randomized controlled trials involving dipyridamole in patients with previous ischemic stroke or TIA were sought from searches of the Cochrane Library, other electronic databases, references lists, earlier reviews, and contact with the manufacturer of dipyridamole." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 7.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 7.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 7.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "Given that isotretinoin is a treatment prescribed most frequently for adolescents and young adults and that cerebral ischemia can produce serious handicaps, an evaluation of vascular risk should be made prior to treatment with this drug." | 7.74 | Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 6.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| "Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator." | 6.46 | Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010) |
| "A review is given on the clinical studies performed with aspirin in patients with chronic vascular occlusions of the limbs and on studies in cerebral ischemia using aspirin and sulfinpyrazone." | 6.14 | Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. ( Breddin, K, 1977) |
| "Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke." | 5.20 | Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 5.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| "Treatment with combined Asp/ER-DP vs clopidogrel in 1360 patients with acute, mild ischemic stroke did not differ in terms of effects on functional outcome, recurrence, death, bleeding, or serious adverse events." | 5.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "This pilot study showed equal efficacy and tolerability of the combination group and aspirin alone in acute intervention treatment for prevention of recurrent stroke or vascular death within 6 months." | 5.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 5.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 5.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| "It is unlikely that dipyridamole leads to a permanent reduction in blood pressure and that this would explain why this drug might prevent strokes rather than coronary events." | 5.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 4.90 | Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "A 23-year-old woman developed ischemic stroke (IS) 8 to 12 hours after ingestion of sumatriptan (ST) and then developed mucosal bleeding secondary to acute thrombocytopenia likely due to dipyridamole (DP) on the 10th day poststroke." | 4.87 | Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy. ( Adams, C; Ames, PR; Dhirendra, A, 2011) |
| "To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease." | 4.87 | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011) |
| "In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women." | 4.85 | Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009) |
| " Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive." | 4.85 | Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009) |
| "In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke." | 4.84 | Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? ( Algra, A; Halkes, PH, 2007) |
| "Randomized controlled trials involving dipyridamole in patients with previous ischemic stroke or TIA were sought from searches of the Cochrane Library, other electronic databases, references lists, earlier reviews, and contact with the manufacturer of dipyridamole." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 3.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 3.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 3.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "Given that isotretinoin is a treatment prescribed most frequently for adolescents and young adults and that cerebral ischemia can produce serious handicaps, an evaluation of vascular risk should be made prior to treatment with this drug." | 3.74 | Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "Using a rat model of cerebral ischemia, the ENT1 inhibitor nitrobenzylmercaptopurine ribonucleoside (NBMPR) significantly increased post-ischemic forebrain adenosine levels and significantly decreased hippocampal neuron injury relative to saline-treatment." | 3.73 | Astrocytes and neurons: different roles in regulating adenosine levels. ( Parkinson, FE; Xiong, W; Zamzow, CR, 2005) |
| "Individual patient data of the second European Stroke Prevention Study (n=6602), in which patients with a previous transient ischemic attack or ischemic stroke were randomized to aspirin, dipyridamole, their combination, or placebo, were reanalyzed." | 3.73 | Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006) |
| "In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns." | 3.72 | Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003) |
| " Therefore, it was aimed to study whether dipyridamole (CAS 58-32-2), an adenosine uptake inhibitor, or adenosine (CAS 58-61-7) could affect the rat brain gamma-aminobutyric acid (GABA, CAS 56-12-2) level after induction of cerebral ischemia, and to test their effect on the lactate dehydrogenase (LDH) activity of the ischemic rat brain." | 3.71 | Influence of inhibition of adenosine uptake on the gamma-aminobutyric acid level of the ischemic rat brain. ( Khattab, M; Seif-el-Nasr, M, 2002) |
| " Apart from the standard remedies, the authors administered drugs affecting the syndrome of disseminated intravascular coagulation, such as dipyridamole, glutamic acid and phytin, with heparin and freshly frozen plasma containing antithrombin III employed in grave cases." | 3.67 | [Treatment of the syndrome of disseminated intravascular coagulation in ischemic strokes]. ( Bova, IIa; Karlov, VA; Makarov, VA, 1984) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 2.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| "Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction." | 2.68 | [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996) |
| "The number of fatal and non fatal cerebral infarction was 31 in the P group, 17 in the ASA group, and 18 in the ASA + D group." | 2.65 | [The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results]. ( Bousser, MG; Eschwege, E; Haguenau, M; Lefauconnier, JM; Thibult, N; Touboul, D; Touboul, PJ, 1983) |
| "Predictive performance in patients with cerebral ischemia was poor." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| "Dipyridamole was introduced into clinical medicine in the early 1960s as a coronary vasodilator." | 2.46 | Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia. ( Cipriani, S; Corti, F; Melani, A; Pedata, F, 2010) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "Ticlopidine is a reserve drug due to its unfavorable side effect profile (neutropenia, TTP)." | 2.42 | [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review]. ( Jüttler, E; Meyding-Lamadé, UK; Schellinger, PD; Schwark, C, 2004) |
| "Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia." | 2.41 | Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| " In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)." | 1.35 | Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Dipyridamole (0." | 1.29 | Brain SPECT with dipyridamole stress to evaluate cerebral blood flow reserve in carotid artery disease. ( Brannon, WL; Farrell, JJ; Hwang, TL; Saenz, A, 1996) |
| "62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution." | 1.27 | Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. ( Calandre, L; Molina, JA, 1985) |
| "Mitral valve prolapse is usually a benign condition, however, serious complications have been reported to be associated with it." | 1.27 | Mitral valve prolapse and thromboembolic disease in pregnancy: a case report. ( Bergh, PA; Breen, JL; Gregori, CA; Hollander, D, 1988) |
| "When dipyridamole was infused in 11 healthy subjects, the adenosine level was not significantly elevated but the platelet aggregation was inhibited (from 13 to 11 ohms, p less than 0." | 1.27 | Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole. ( Edlund, A; Sidén, A; Sollevi, A, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 26 (20.31) | 18.7374 |
| 1990's | 18 (14.06) | 18.2507 |
| 2000's | 49 (38.28) | 29.6817 |
| 2010's | 31 (24.22) | 24.3611 |
| 2020's | 4 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, J | 1 |
| Liu, S | 1 |
| Yu, W | 1 |
| Lim, ST | 1 |
| Murphy, SJX | 1 |
| Murphy, SM | 1 |
| Coughlan, T | 2 |
| O'Neill, D | 2 |
| Tierney, S | 1 |
| Egan, B | 1 |
| Collins, DR | 1 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Smith, DR | 1 |
| Cox, D | 2 |
| McCabe, DJH | 1 |
| Woodhouse, LJ | 4 |
| Appleton, JP | 3 |
| Christensen, H | 3 |
| Dineen, RA | 3 |
| England, TJ | 3 |
| James, M | 3 |
| Krishnan, K | 3 |
| Montgomery, AA | 2 |
| Ranta, A | 3 |
| Robinson, TG | 3 |
| Sprigg, N | 4 |
| Bath, PM | 10 |
| Kimpton, J | 1 |
| Khong, T | 1 |
| Lana, D | 1 |
| Ugolini, F | 1 |
| Melani, A | 2 |
| Nosi, D | 1 |
| Pedata, F | 2 |
| Giovannini, MG | 1 |
| Beridze, M | 2 |
| Duley, L | 2 |
| Flaherty, K | 2 |
| Havard, D | 1 |
| Heptinstall, S | 3 |
| Markus, HS | 3 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Scutt, P | 2 |
| Venables, GS | 2 |
| Barlas, RS | 1 |
| Loke, YK | 1 |
| Mamas, MA | 1 |
| Bettencourt-Silva, JH | 1 |
| Ford, I | 1 |
| Clark, AB | 1 |
| Bowles, KM | 1 |
| Metcalf, AK | 1 |
| Potter, JF | 1 |
| Myint, PK | 1 |
| Lee, M | 1 |
| Saver, JL | 2 |
| Hong, KS | 1 |
| Rao, NM | 1 |
| Wu, YL | 1 |
| Ovbiagele, B | 2 |
| Sandercock, PA | 1 |
| Counsell, C | 1 |
| Tseng, MC | 1 |
| Cecconi, E | 1 |
| Davidai, G | 1 |
| Cotton, D | 4 |
| Gorelick, P | 3 |
| Lipton, RB | 1 |
| Sacco, R | 2 |
| Diener, HC | 9 |
| Robson, K | 1 |
| Dineen, R | 1 |
| Pocock, S | 2 |
| Fabiaña, N | 1 |
| Ramaswami, AP | 1 |
| Ang, ES | 1 |
| De Silva, DA | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Olesen, JB | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Kristensen, SL | 1 |
| Gislason, G | 1 |
| Torp-Pedersen, C | 1 |
| Hilkens, NA | 1 |
| Algra, A | 9 |
| Greving, JP | 1 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| McCabe, DJ | 2 |
| Sztriha, LK | 1 |
| Vécsei, L | 1 |
| Albers, GW | 2 |
| Amarenco, P | 1 |
| Easton, JD | 1 |
| Sacco, RL | 4 |
| Teal, P | 2 |
| Yusuf, S | 3 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 2 |
| Martin, RH | 3 |
| Bath, P | 2 |
| Bornstein, N | 1 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Cunha, L | 2 |
| Dahlöf, B | 1 |
| De Keyser, J | 1 |
| Donnan, GA | 2 |
| Estol, C | 2 |
| Gu, V | 1 |
| Hermansson, K | 2 |
| Hilbrich, L | 1 |
| Kaste, M | 2 |
| Lu, C | 1 |
| Machnig, T | 1 |
| Pais, P | 1 |
| Roberts, R | 2 |
| Skvortsova, V | 1 |
| Toni, D | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Yoon, BW | 1 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Minnerup, J | 1 |
| Schäbitz, WR | 1 |
| Hart, RG | 1 |
| Hegge, KA | 1 |
| Halkes, PH | 2 |
| van Gijn, J | 2 |
| Kappelle, LJ | 2 |
| Koudstaal, PJ | 2 |
| Leys, D | 1 |
| Balucani, C | 1 |
| Cordonnier, C | 1 |
| Biller, J | 1 |
| De Schryver, EL | 3 |
| Beckman, JA | 1 |
| Adams, C | 1 |
| Dhirendra, A | 1 |
| Ames, PR | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Meyer, D | 1 |
| Diedler, J | 1 |
| Ahmed, N | 1 |
| Sykora, M | 1 |
| Uyttenboogaart, M | 1 |
| Overgaard, K | 2 |
| Luijckx, GJ | 1 |
| Soinne, L | 1 |
| Ford, GA | 1 |
| Lees, KR | 2 |
| Wahlgren, N | 1 |
| Ringleb, P | 1 |
| Burke, JP | 1 |
| Sander, S | 1 |
| Shah, H | 1 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Cipriani, S | 1 |
| Corti, F | 1 |
| Serebruany, V | 1 |
| Sani, Y | 1 |
| Pokov, I | 1 |
| Schevchuck, A | 1 |
| Fong, A | 1 |
| Thevathasan, L | 1 |
| Hanley, D | 1 |
| Khan, M | 1 |
| Kamal, AK | 2 |
| Uchiyama, S | 1 |
| Ikeda, Y | 1 |
| Urano, Y | 1 |
| Horie, Y | 1 |
| Yamaguchi, T | 1 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Martin Saborido, C | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Fisher, M | 1 |
| Vinisko, R | 1 |
| Weber, R | 1 |
| Weimar, C | 1 |
| Wanke, I | 1 |
| Möller-Hartmann, C | 1 |
| Gizewski, ER | 1 |
| Blatchford, J | 1 |
| Demchuk, AM | 1 |
| Forsting, M | 1 |
| Warach, S | 1 |
| Diehl, A | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Geeganage, CM | 1 |
| Chen, C | 1 |
| Topol, EJ | 1 |
| Dengler, R | 2 |
| Bath, MW | 1 |
| Arnarsdottir, L | 1 |
| Hjalmarsson, C | 1 |
| Bokemark, L | 1 |
| Andersson, B | 1 |
| Worthmann, H | 1 |
| Schumacher, H | 1 |
| Schwartz, A | 1 |
| Eisert, WG | 1 |
| Lichtinghagen, R | 1 |
| Weissenborn, K | 1 |
| Kinsella, JA | 1 |
| Tobin, WO | 1 |
| Collins, R | 1 |
| Murphy, RP | 1 |
| Wadiwala, MF | 1 |
| Milionis, H | 1 |
| Michel, P | 1 |
| Mehta, P | 1 |
| Aslanyan, S | 1 |
| Fazekas, F | 1 |
| Weir, CJ | 1 |
| Horner, S | 1 |
| Schellinger, PD | 3 |
| Jüttler, E | 1 |
| Meyding-Lamadé, UK | 1 |
| Schwark, C | 2 |
| Serebruany, VL | 1 |
| Malinin, AI | 1 |
| Sane, DC | 1 |
| Jilma, B | 1 |
| Takserman, A | 1 |
| Atar, D | 1 |
| Hennekens, CH | 1 |
| Leonardi-Bee, J | 3 |
| Bousser, MG | 5 |
| Davalos, A | 2 |
| Guiraud-Chaumeil, B | 1 |
| Sivenius, J | 3 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Moussouttas, M | 2 |
| Papamitsakis, N | 1 |
| Zhao, L | 2 |
| Fletcher, S | 1 |
| Weaver, C | 1 |
| May, J | 1 |
| Fox, S | 1 |
| Willmot, M | 1 |
| Heptinstal, S | 1 |
| Ringleb, PA | 1 |
| Schwaninger, M | 1 |
| Parkinson, FE | 1 |
| Xiong, W | 1 |
| Zamzow, CR | 1 |
| Szapáry, L | 1 |
| Ariesen, MJ | 1 |
| Gray, L | 1 |
| Weaver, CS | 1 |
| Jonas, S | 1 |
| Grieco, G | 1 |
| Chairangsarit, P | 1 |
| Sithinamsuwan, P | 1 |
| Niyasom, S | 1 |
| Udommongkol, C | 1 |
| Nidhinandana, S | 1 |
| Suwantamee, J | 1 |
| O'Donnell, M | 1 |
| Eikelboom, JW | 1 |
| Flaherty, ML | 1 |
| Kissela, B | 1 |
| Broderick, JP | 1 |
| Derendorf, H | 1 |
| Einhäupl, K | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Sudlow, C | 1 |
| Laroche, ML | 1 |
| Macian-Montoro, F | 1 |
| Merle, L | 1 |
| Vallat, JM | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 1 |
| Rojas, A | 1 |
| González, I | 1 |
| Figueroa, H | 1 |
| Hallevi, H | 1 |
| Hazan-Hallevi, I | 1 |
| Paran, E | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Alberts, MJ | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 1 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Johnston, SC | 1 |
| Katzan, I | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Schwamm, LH | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Karlov, VA | 1 |
| Makarov, VA | 1 |
| Bova, IIa | 1 |
| Hinton, RC | 1 |
| Eschwege, E | 3 |
| Haguenau, M | 3 |
| Lefauconnier, JM | 3 |
| Thibult, N | 2 |
| Touboul, D | 3 |
| Touboul, PJ | 3 |
| Ordinas, A | 1 |
| Sancho Rieger, J | 1 |
| López-Trigo Picho, J | 1 |
| Burtsev, EM | 1 |
| Usov, LA | 1 |
| Atamaniuk, ED | 1 |
| Miller, LG | 1 |
| Hansen, PE | 1 |
| Hansen, JH | 1 |
| Stenbjerg, S | 1 |
| Marshall, M | 1 |
| Cauchie, C | 1 |
| Croveri, G | 1 |
| Santos, MT | 1 |
| Vallés, J | 2 |
| Aznar, J | 2 |
| Yayá, R | 2 |
| Perez-Requejo, JL | 1 |
| Hegedüs, K | 1 |
| Fekete, I | 1 |
| Molnár, L | 1 |
| Díaz-Marín, C | 1 |
| Matías-Guiu, J | 2 |
| Hwang, TL | 1 |
| Saenz, A | 1 |
| Farrell, JJ | 1 |
| Brannon, WL | 1 |
| Rosa, A | 1 |
| Canaple, S | 1 |
| Rosendaal, FR | 1 |
| Orberk, E | 1 |
| Hacke, W | 1 |
| Gorter, JW | 1 |
| Boysen, G | 1 |
| Forbes, C | 1 |
| Laakso, M | 1 |
| Lowenthal, A | 1 |
| Smets, P | 1 |
| Riekkinen, P | 2 |
| Scott, G | 1 |
| Scott, HM | 1 |
| Mosso, M | 1 |
| Baumgartner, RW | 1 |
| Stakhovskaia, LV | 1 |
| Kvasova, OV | 1 |
| Prianikova, NA | 1 |
| Efremova, NM | 1 |
| Skvortsova, VI | 1 |
| Bergmann, SR | 1 |
| Seif-el-Nasr, M | 1 |
| Khattab, M | 1 |
| Breddin, K | 1 |
| Urbinati, S | 1 |
| Di Pasquale, G | 1 |
| Andreoli, A | 1 |
| Lusa, AM | 1 |
| Lanzino, G | 1 |
| Grazi, P | 1 |
| Ruffini, M | 1 |
| Labanti, G | 1 |
| Pinelli, G | 1 |
| Fogelholm, R | 1 |
| Park, TS | 1 |
| Gidday, JM | 1 |
| Calandre, L | 1 |
| Molina, JA | 1 |
| Chrobocek, J | 1 |
| Phillis, JW | 1 |
| O'Regan, MH | 1 |
| Walter, GA | 1 |
| Caneschi, S | 1 |
| Bonaventi, C | 1 |
| Finzi, F | 1 |
| Bergh, PA | 1 |
| Hollander, D | 1 |
| Gregori, CA | 1 |
| Breen, JL | 1 |
| Joseph, R | 1 |
| D'Andrea, G | 1 |
| Oster, SB | 1 |
| Welch, KM | 1 |
| Gordon, RL | 1 |
| Haskell, L | 1 |
| Hirsch, M | 1 |
| Shifrin, E | 1 |
| Weinman, E | 1 |
| Romanoff, H | 1 |
| Picó, M | 1 |
| Monasterio, J | 1 |
| Vilaseca, J | 1 |
| Codina, A | 1 |
| Edlund, A | 1 |
| Sidén, A | 1 |
| Sollevi, A | 1 |
| Yamashita, T | 1 |
| Kikuchi, H | 1 |
| Ihara, I | 1 |
| Matsumoto, A | 1 |
| Vinichuk, SM | 1 |
| Malyĭ, VD | 1 |
| Vayá, A | 1 |
| Villa, P | 1 |
| Santos, T | 1 |
| Martinez-Sales, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid[NCT00311402] | Phase 3 | 1,295 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744] | 3,400 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 9 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 16 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 12 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 7 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 71 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 55 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 45 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 32 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 13 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 13 |
This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 51 |
This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 11 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 6 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 39 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 0 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 1 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 3 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 3 |
35 reviews available for dipyridamole and Brain Ischemia
| Article | Year |
|---|---|
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle | 2014 |
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
Multifunctional actions of approved and candidate stroke drugs.
Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha | 2009 |
What's new in stroke? The top 10 studies of 2006-2008. Part I.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
Antiplatelet agents for prevention of recurrent ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic | 2009 |
Antiplatelet drugs for ischemic stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Secondary stroke prevention with antithrombotic drugs.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug | 2010 |
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, | 2009 |
Ischemic stroke followed by acute thrombocytopenia: a double iatrogenic whammy.
Topics: Acute Disease; Adult; Brain Ischemia; Dipyridamole; Female; Hemorrhage; Humans; Iatrogenic Disease; | 2011 |
Antiplatelets and stroke outcomes: state of the science.
Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy | 2009 |
Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.
Topics: Animals; Brain Ischemia; Carotid Artery, Common; Dipyridamole; Disease Models, Animal; Humans; Infus | 2010 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S | 2013 |
Aspirin in the prophylaxis of coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi | 2002 |
[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Dose-Response Relation | 2004 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
Combination antiplatelet agents in ischemic cerebrovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2005 |
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2007 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2007 |
Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stro | 2007 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib | 1983 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
[Antithrombotic therapy after cerebral ischemia].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, | 1997 |
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel | 1998 |
[Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. Diagnosis, differential diagnosis and treatment].
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Dipyridamole; Endarterectomy, | 2000 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
[The use of drugs that affect thrombocytes in cerebral ischemia].
Topics: Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Female; Humans; Male; Ticlopidine | 1990 |
30 trials available for dipyridamole and Brain Ischemia
| Article | Year |
|---|---|
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation | 2015 |
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2017 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla | 2010 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Comorbidity; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2012 |
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Chemokine CCL2; Dipyridamole; D | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2012 |
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up | 2003 |
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Di | 2004 |
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog | 2005 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study.
Topics: Aged; Aspirin; Brain Ischemia; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination | 2005 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib | 1983 |
[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results].
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 1983 |
["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; | 1981 |
[Controlled cooperative trial. Secondary prevention of atherosclerosis-related cerebral ischemic accidents by aspirin dipyridamole. 2: Description of subjects at the beginning of the trial].
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug The | 1982 |
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re | 1996 |
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?].
Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Brain Ischemia; Cerebrovascular Disor | 1998 |
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; | 1999 |
[The administration of dipyridamole (curantil) for the secondary prevention of ischemic stroke].
Topics: Acute Disease; Aged; Brain; Brain Ischemia; Dipyridamole; Dose-Response Relationship, Drug; Female; | 2000 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
Second European Stroke Prevention Study. ESPS-2 Working Group.
Topics: Aspirin; Brain Ischemia; Computer Simulation; Dipyridamole; Double-Blind Method; Drug Administration | 1992 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks.
Topics: Adult; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; D | 1987 |
Effect of dipyridamole plus pentoxifylline in patients with diffuse cerebrovascular insufficiency.
Topics: Aged; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Female; Hum | 1985 |
65 other studies available for dipyridamole and Brain Ischemia
| Article | Year |
|---|---|
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |
Intensive antiplatelet therapy with three agents does not reduce risk of another stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke | 2020 |
The neuron-astrocyte-microglia triad in CA3 after chronic cerebral hypoperfusion in the rat: Protective effect of dipyridamole.
Topics: Analysis of Variance; Animals; Apoptosis; Astrocytes; Brain Ischemia; CA3 Region, Hippocampal; Carot | 2017 |
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2018 |
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; | 2014 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; | 2015 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions; | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Arteries; Dipyridamole; Drug Therapy, Combination; Female; H | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Dose-Response Relationship | 2012 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo | 2003 |
Effect of blood pressure during the acute period of ischemic stroke on stroke outcome: a tertiary analysis of the GAIN International Trial.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Blood Pressure; Brain Isc | 2003 |
Astrocytes and neurons: different roles in regulating adenosine levels.
Topics: Adenosine; Affinity Labels; Animals; Astrocytes; Brain Ischemia; Cells, Cultured; Deoxyglucose; Dipy | 2005 |
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle | 2006 |
Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Human | 2006 |
ESPRIT trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Dipyridamole; Drug Interactions; G | 2006 |
ESPRIT trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Dose | 2006 |
Clinical trials and dipyridamole formulation selection.
Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug | 2007 |
Emerging therapies: ESPRIT.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 2007 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
Cerebral ischemia probably related to isotretinoin.
Topics: Adult; Aspirin; Brain Ischemia; Dermatologic Agents; Dipyridamole; Heparin; Humans; Isotretinoin; Ma | 2007 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Re: Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan.
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line, Transformed; Dipyridam | 2008 |
The ECV-304 cell-line: should it be used?
Topics: Benzimidazoles; Biphenyl Compounds; Brain Ischemia; Cell Adhesion; Cell Line; Dipyridamole; Endothel | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
[Treatment of the syndrome of disseminated intravascular coagulation in ischemic strokes].
Topics: Adult; Aged; alpha-Tocopherol; Blood Transfusion; Brain Ischemia; Combined Modality Therapy; Dipyrid | 1984 |
Treatment of cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; H | 1981 |
[Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
Topics: Brain Ischemia; Dipyridamole; Drug Evaluation; Female; Gastrointestinal Hemorrhage; Humans; Male; Re | 1984 |
[Experimental and clinical study of the efficacy of intracarotid administration of curantil in the treatment of cerebral ischemia].
Topics: Adult; Animals; Brain; Brain Ischemia; Carotid Artery, Internal; Catheterization; Cats; Cerebral Inf | 1983 |
Platelet aggregation in focal cerebral ischemia -a clinical study.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
[Ischemic cerebro-vascular accidents: usefulness of anticoagulant and antiaggregating agents (author's transl)].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Plat | 1981 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
Effects of dipyridamole, pentoxifylline or dipyridamole plus pentoxifylline on platelet reactivity in patients with ischemic cerebrovascular insufficiency.
Topics: Aged; Blood Platelets; Brain Ischemia; Collagen; Dipyridamole; Drug Therapy, Combination; Female; Hu | 1993 |
Effects of dipyridamole in spontaneously hypertensive rabbits with diffuse chronic cerebral ischemia.
Topics: Analysis of Variance; Animals; Blood Pressure; Brain Ischemia; Cerebrovascular Circulation; Dipyrida | 1993 |
[Stroke in young people].
Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Child; Dipyridamole; Female; Humans; Male; Middle Aged; | 1996 |
Brain SPECT with dipyridamole stress to evaluate cerebral blood flow reserve in carotid artery disease.
Topics: Acetazolamide; Aged; Brain; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Inf | 1996 |
Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhib | 1997 |
[Prevention of thrombosis after ischemic cerebrovascular attack--new possibilities].
Topics: Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Dipyridamole; Humans; Intracranial Embolism | 1998 |
Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis.
Topics: Aspirin; Brain Ischemia; Costs and Cost Analysis; Dipyridamole; Health Care Costs; Humans | 1997 |
Alert to physicians: possible interaction of aggrenox and adenosine.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparati | 2000 |
Influence of inhibition of adenosine uptake on the gamma-aminobutyric acid level of the ischemic rat brain.
Topics: Adenosine; Animals; Biomarkers; Brain; Brain Chemistry; Brain Ischemia; Cerebral Cortex; Dipyridamol | 2002 |
Heart-brain interactions in cerebral ischaemia: a non-invasive cardiologic study protocol.
Topics: Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Dipyridamole; Echocardiography; Electro | 1992 |
[Drug treatment of ischemic disturbances of circulation in the brain].
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Ticlopidine | 1990 |
Effect of dipyridamole on cerebral extracellular adenosine level in vivo.
Topics: Adenosine; Animals; Brain; Brain Ischemia; Cerebral Cortex; Dialysis; Dipyridamole; Extracellular Sp | 1990 |
Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female; | 1985 |
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage].
Topics: Aspirin; Brain Ischemia; Dipyridamole; Female; Hemiplegia; Humans; Male; Middle Aged; Pentoxifylline | 1989 |
Effects of two nucleoside transport inhibitors, dipyridamole and soluflazine, on purine release from the rat cerebral cortex.
Topics: Adenosine; Animals; Biological Transport, Active; Brain Ischemia; Cerebral Cortex; Dipyridamole; Mal | 1989 |
[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].
Topics: Adenosine Diphosphate; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Isoxsuprine; Male; Oxa | 1985 |
Mitral valve prolapse and thromboembolic disease in pregnancy: a case report.
Topics: Adult; Aspirin; Brain Ischemia; Contraceptives, Oral; Dipyridamole; Drug Therapy, Combination; Embol | 1988 |
Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.
Topics: Acute Disease; Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dipyridam | 1989 |
Transluminal dilatation of the subclavian artery.
Topics: Adult; Aged; Angioplasty, Balloon; Arm; Brain Ischemia; Constriction, Pathologic; Dipyridamole; Fema | 1985 |
Evidence for an anti-aggregatory effect of adenosine at physiological concentrations and for its role in the action of dipyridamole.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Brain Ischemia; Dipyridamole; Female; Humans; In Vitr | 1987 |
[The effect of artificial hypotension on postischemic cerebral edema in the reperfusion of middle cerebral arterial occlusion in cats--experimental study].
Topics: Adenosine Triphosphate; Animals; Body Water; Brain Chemistry; Brain Edema; Brain Ischemia; Cats; Cer | 1986 |
[Hemodynamic disorders and various problems in treatment in strokes with reversible neurologic deficits].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bencyclane; Brain Ischemia; Dipyridamole; Diuretics; | 1986 |